Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Ino save search
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
Published: 2021-12-14 (Crawled : 13:30) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: -1.56%
H: 0.67%
C: -1.34%
vgx-3100 treatment hpv immunotherapy therapy phase 3
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Published: 2021-10-11 (Crawled : 12:00) - prnewswire.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: -1.21%
H: 5.95%
C: 3.82%
covid vaccine phase 3 authorized ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Published: 2021-04-23 (Crawled : 12:15) - inovio.com
INO | $10.59 5.69% 41K
|
Health Technology
|
| O: -27.71%
H: 6.67%
C: 3.79%
phase 3 trial ino-4800
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
KULR | $0.5446 22.0% 6.8M
|
Manufacturing
MDIA 4 | $2.205 21.15% 150K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.